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Abstract
Background:  The COOH terminal peptide of Pro-collagen type I (PICP, also called C3) is
chemotactic for endothelial melanoma and breast cancer cells. PICP induces the expression of
Metalloproteinases-2 and -9, of Vascular endothelial growth factor and of the chemokine CXCL-
12 receptor CXCR4 in MDA MB231 breast carcinoma cells in vitro.
Methods: We used a model of xenografts in BalbC/nude mice obtaining tumors by implanting in
contro-lateral subcutaneous positions MDA MB231 cells added or not with purified PICP and
studied the earlier phases of tumor development, up to 48 days from implant, by histology,
immunostain and in situ hybridization.
Results: Addition of PICP promotes rapid vascularization of the tumors while does not affect
mitotic and apoptotic indexes and overall tumor growth. PICP-treated, relative to control tumors,
show up-modulation of Vascular endothelial factor, Metalloproteinase-9 and CXCR4, all tumor
prognostic genes; they also show down-modulation of the endogenous Metalloproteinase inhibitor,
reversion-inducing-cysteine-rich protein with kazal motifs, and a different pattern of modulation of
Tissue Inhibitor of Metalloproteinase-2. These changes occur in absence of detectable expression
of CXCL-12, up to 38 days, in control and treated tumors.
Conclusion: PICP has an early promoting effect in the acquisition by the tumors of prometastatic
phenotype. PICP may be play a relevant role in the productive interactions between stroma and
tumor cells by predisposing the tumor cells to respond to the proliferation stimuli ensuing the
activation of signaling by engagement of CXCR4 by cytokines and by fostering their extravasion,
due to the induction of increased vascular development.
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Background
Peritumoral stroma is involved in the development of
tumors, induces changes in gene expression conductive to
cancer progression and promotes inflammation, angio-
genesis and metastasis [1-6]. In breast carcinomas changes
occur in the expression of genes involving all tumor-infil-
trating cell types [7]. In breast cancer, stromal fibroblasts
respond to pre-tumoral cells by undergoing epigenetic
changes, which lead to altered molecular composition of
the extracellular matrix (ECM) [8,9], with increased depo-
sition of collagens, fibronectin and tenascin [10], and
increase in inflammatory cytokines and growth factors,
such as VEGF and CXCL-12, which promote vascular
development and cancer cell proliferation and invasive-
ness [11-15].
Vascular endothelial Growth factor (VEGF)-A is a major
angiogenic factor. The activation of an autocrine loop of
VEGF-A signaling required for breast carcinoma invasion
in vitro, is mediated by the receptor Neuropilin-1(Nrp-1),
but not the receptor Flt-1 [15]. Down regulation of the
inhibitory forms of VEGF-A (VEGF-xxxb), due to differen-
tial splicing at the C terminus, is accompanied by up-
modulation of total VEGF-A and is associated with tumor
progression and angiogenesis [16].
Autocrine VEGF regulates the expression of the chemok-
ine receptor CXCR4, which mediates the migration of
breast carcinoma cells toward CXCL-12, required for
tumor cells invasion but not for their survival [17]. The
activation of a paracrine loop CXCR4/CXCL-12 involving
tumor cells and stromal fibroblasts induces tumor growth
in implants of MCF-7 breast carcinoma cells with cancer
associated fibroblasts (CAF) [14]. Activation of CXCR4/
CXCL-12 signaling plays a critical role in growth and inva-
sion of primary and metastatic breast tumors [14,18-21];
CXCR-4 expression is a hallmark of a subset of stem breast
cancer cells, with metastatic behavior and homing to
bone.
Cancer development also involves ECM degradation by
proteases, involved in the migration of tumor cells and
leading to the release of growth factors and cytokines
stored in the matrix and active in regulating the survival,
growth and invasiveness of cancer cells and in angiogen-
esis. Several proteases are implied in oncogenesis; among
them members of the family of Metalloproteinases
(MMP) are up modulated in neoplastic stroma [21-24]; In
particular, over expression of MMP-9 is associated with
malignancy and poor prognosis in breast cancer [25].
The metastatic phenotype implies multiple changes; in
particular co-expression of CXCR4, VEGF-A and MMP-9 is
strongly correlated with lymph node metastasis and is a
prognostic marker of the metastatic ability of primary
breast cancer [26].
The membrane-anchored MMP-regulator reversion-
inducing-cysteine-rich protein with kazal motifs (RECK)
regulates tumor invasiveness and, via direct interaction,
negatively regulates MMP-9 and inhibits tumor invasion
and metastasis [27,28]. RECK down regulation in solid
tumors correlates with poor prognosis, while its forced
expression in tumor cells results in suppression of angio-
genesis, invasion, and metastasis and restoring expression
of RECK in malignant cells results in suppression of inva-
sive activity and decrease in MMP-9 secretion [29]. RECK
also inhibits MMP-2 and MT1-MMP, also involved in can-
cer progression. Vascular sprouting is suppressed in
ectopic tumors derived from RECK-expressing fibrosar-
coma cells, implicating RECK also in tumor angiogenesis
[30].
Tissue inhibitor of Metalloproteinases (TIMP)-2 is a ste-
chiometric cofactor in MT1-MMP-dependent MMP-2 acti-
vation and, in excess, it acts as inhibitor of MMP-2 [31]. In
prostate cancer TIMP2 and MMP2 over expression was sig-
nificantly associated with a shorter disease free survival
[32].
The COOH terminal peptide of Pro-collagen type I (PICP)
is a stromal component produced by the proteolytic cleav-
age of pro-collagen I by Bone Morphogenetic Protein I
during the physiological processing of collagen fibers.
PICP is abundant in tissues with high expression of colla-
gen I such as bone and the stroma of breast cancer and
high levels of PICP are found in the sera of breast cancer
patients and are associated with poor prognosis [33,34].
PICP induces directional migration and increased expres-
sion of MMP-2 and -9 in various breast carcinoma and
melanoma cell lines and chemo attracts endothelial cells
[35-37]. In MDA MD231 cells, PICP induces the expres-
sion of MT-1 MMP, MMP-2 and -9 and TIMP-2 and, in a
timely succession, that of VEGF-A, -B and Nrp-1 mRNAs
and VEGF-A protein, mediated by activation of p-38, and
of CXCR4 mRNA and protein [35,36]. Furthermore, PICP
is chemoattractant for endothelial cells in vitro [37]. These
data lead us to hypothesize that PICP induces epigenetic
changes in breast tumor cells, resulting in promotion of
tumor vascularization and progression in vivo.
We have observed in BalbC/nude mice that subcutaneous
inoculations of MDA MB231 cells treated with PICP
results in tumors that are more vascularized than
untreated, contro-lateral, tumors. Pro-metastatic genes
(VEGF-A, MMP-9 and CXCR4) are up-regulated, and the
tumor inhibitory gene (RECK) is down-regulated in
xenograft tumors developing in presence of PICP.
Growth, apoptotic and mitotic indexes of tumors areBMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
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unaffected by PICP treatment. The results point to an epi-
genetic role for PICP in promoting breast tumor progres-
sion through the induction of the expression of genes
associated to metastasis and vascularization.
Methods
Cell cultures and preparation of PICP
The breast carcinoma MDA MB231 cell line was cultured
in DMEM 10% FCS. PICP was purified from serum free
medium conditioned by mature rat osteoblasts as previ-
ously described (37). The MDA MB231 cell line expresses
low endogenous levels of CXCR4, stimulated by PICP in
vitro and does not express CXCL-12 in presence or
absence of PICP.
Xenografts
Six-to-eight week old females BalbC/nude mice (Charles
River, Italy) were housed at 12-hour light/dark cycle at
22°C and fed ad libitum. Animals were treated according
to the standards approved by the Ethical committee of the
Istituto Nazionale per la Ricerca sul Cancro (National
Institute or Cancer Research, IST). Mice were injected sub-
cutaneously with 1 × 106 MDA-MB231 cells embedded in
150 μl of Growth Factors-free matrigel (Becton Dickinson,
USA) in PBS added or not with PICP. Injections were per-
formed bilaterally in the dorsal side, each animal receiv-
ing on one side cells added with PICP and on the other
cells in PBS. Thereafter, mice were injected weekly with 30
μl of either PBS or PICP at the site of the original implant.
All injected mice developed tumors. Tumors size was eval-
uated three times per week with a caliper. Mice were sacri-
ficed after 7, 14, 21 or 28 days from implantation in a set
of experiments and or after 24, 31,38,48 in another. At
each time point six to ten animals were sacrificed. Tumors
were dissected, weighted and fixed overnight in 4% para-
formaldehyde at 4°C, washed extensively in PBS, satu-
rated with increasing concentrations of sucrose and
embedded in O.C.T. (Tissue-Tek) for preservation at -
80°C or in paraffin. Serial sections 6 μm thick from crio-
preserved tumors were used for morphology (hematoxy-
lin-eosin stain), mitotic and apoptotic indexes
determination (by Giemsa and Hoechst stains) and CD31
detection by immunohistochemistry and immunofluo-
rescence. Paraffin embedded tumors were sectioned in 4
μm tick slices and used for in situ hybridization and all
other immunohistochemistry. Images were captured with
the Olympus Camedia Digital camera C3030 attached to
an Olympus BX51 Microscope (Japan).
Mitotic and apoptotic indexes
Criopreserved tumors were sectioned and slices were
treated either with Giemsa stain (3% in Sorensen's buffer,
pH 6.8, 30') or Hoechst 33258 stain (0.2 mM in phop-
sphate-buffered saline PBS 40' in the dark) at room tem-
perature. These last slides were mounted with Vectashield
and cells were scored using a UG1 excitation filter and a
combination of dichroid mirrors and secondary filters
transmitting light at 460–500 nm. Scoring was done an
Axioplan Zeiss fluorescence microscope (Germany)
equipped with a two-wavelength filter combination. For
each slide a minimum of 1,000 cells were scored in ran-
domly chosen fields.
Immunohistochemistry and immunofluorescence
Tumor frozen sections were fixed 10 minutes in cold
methanol:acetone (1:1), blocked in PBS-10% goat serum
and incubated with a rat monoclonal anti-CD31 (from
Dr. Laura Borsi, Italy). Secondary antibodies were anti-rat
either conjugated with TRITC (Sigma), or with biotin
(BioSpa) followed by alkaline phosphatase-conjugated
streptavidin (BioSpa) and developed with Fast Red (Lab-
Vision) in the presence of Levamisole.
From tumors embedded in paraffin slices were processed
for immunoperoxidase after citrate unmasking of the anti-
gen at 95°C, peroxidase quenching, rinses in PBS and
incubation with primary antibody for 60' at room temper-
ature. Incubation for 60' with the secondary antibody
(HRP polymer conjugate broad spectrum DAB kit from
Zymed Laboratories inc., cat 87-9663), was followed by
Haematoxylin/Eosin staining. Controls were without pri-
mary antibody. Primary antibodies were used at 1/50
Dilution for Ab-110 to MMP-9 polyclonal in rabbit
(donated by Dr. W.G. Stetler-Stevenson, CCR, NCI, NIH,
Bethesda, MD, USA), Ab to VEGF-A polyclonal in rabbit
(sc-507, Santa Cruz, USA, recognizing aa 1–140 of VEGF-
A, and thus all forms of VEGF-A), Mab to TIMP-2 mono-
clonal in mouse (MAB13446, Chemicon, USA) and Ab to
CXCL-12 rabbit polyclonal (sc-28876, Santa Cruz). Dilu-
tion were 1/30 for Ab to RECK polyclonal in rabbit (sc-
28918, Santa Cruz) and 1/20 for monoclonal antibody in
mouse to CXCR4 (MAB 170, R&D, USA) and for mono-
clonal antibody in rabbit to CD34 (sc-18917, Santa Cruz,
USA).
In situ hybridization
Probes were: VEGF-A, 700 bp cDNA (recognizing all
VEGF-A mRNA splicing variants) cloned by RT-PCR with
the PCR TA cloning kit (Invitrogen, USA) from human
total RNA (primers VEGF-A human: Lp CCTTGCTGCTC-
TACCTCCAC Rp TCTGTCGATGGTGATGGTGT) in PCR
2.1 vector. CXCR4, 692 bp (recognizing two mRNA splic-
ing variants) cloned by RT-PCR with PCR-Script Amp
cloning kit (Stratagene, USA) from human total RNA
(primer CXCR4 human Lp ATGCAAGGCAGTCCATGT-
CAT Rp TCTGTCGATGGTGATGGTGT) in pPCR-script
amp SK(+) vector.
MMP-9, 1067 bp human cDNA cloned in Puc19 kindly
provided by Prof. W.G. Stetler-Stevenson. Linearized plas-BMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
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mids were used to obtain sense or antisense digoxigenin-
labeled riboprobes with dig-labeling nucleic acids kit
(Boeringher-Mannheim, Germany) from the appropriate
promoter. Ish reactions were performed on serial sections
of 4 μm thick, deparaffined, dehydrated and post-fixed
with 4% PFA pH 9.5 in PBS 1× [39]. After digestion with
HCl 0.2 M and Proteinase K 10 μg/ml at 37°C, hybridiza-
tion was performed in 3× SSC, 1 mg/ml tRNA, 10 mM
DTT, Denhardt's solution 1×, 50% formamide, 1 mg/ml
denatured salmon sperm, 10% dextran sulfate and 1 ng/
μl of the denaturated probe, maintained overnight at high
stringency [40]. Temperatures of annealing and stringency
of washes were optimized for each probe. The slides were
washed in 2× SSC, digested with RNase A 100 μg/ml at
37°C degrees, incubated overnight at 4 degrees with anti-
digoxigenin Fab fragments conjugated to alkaline phos-
phatase (Boeringher-Mannheim, Germany) in buffer with
1.5 M NaCl, 0.1 M TRIS-HCl, 2 mM MgCl2, 0.3% Triton
X-100, 10% fetal calf serum, pH 7.5. Color development
was in buffer 0.1 M NaCl, 0.1 M TRIZMA base, 5 mM
MgCl2, 10% polyvinyl alcohol 89–98 kDa (Sigma, USA),
1 mM levamisole (Sigma, USA), 0.16 mg/ml BCIP, 0.33
mg/ml NBT (Roche, Germany), pH 9.5, for 3–6 hours.
Slides were counter stained with nuclear fast red 0.005%
and mounted in glycerol gelatin (Sigma, USA). Here are
shown exemplary micrographs. The images were captured
with a Leica DMBR microscope mounted with a Leica
camera DFC320 and acquired with Leica Firecam version
1.9.1. For each probe at least two different tumors per
time point were analyzed and gave consisting results.
Statistics
For mitotic and apoptotic indexes standard deviations are
shown. For tumor weight one way ANOVA was utilized to
define significance.
Results and discussion
We chose an ectopic model in BalbC/nude mice for the
generation of tumors by subcutaneous implantation of
MDA MB231 cells, either treated or not with PICP and
injected in contro-lateral locations in each mouse, in
order to decrease the experimental variation due to indi-
vidual differences.
In both control and PICP-treated xenograft tumors, no
differences were observed in mitotic indexes at any of the
experimental times (Fig. 1A). The only exception was for
PICP-treated tumors at 14 days (Fig. 1B). As shown in Fig.
1C this last difference did not affect significantly the
tumor growth: the overall growth of the tumors was simi-
lar in both control and PICP-treated tumors, with the only
significant difference (p = 0.0181) found at 38 days. This
difference disappeared by 48 days and it could be due to
a short delay in the start of the more rapid proliferation
phase that all tumors anyway undertake between 38 and
48 days. Overall, the measures of mitotic and apoptotic
frequencies and of weight indicated lack of any continued
effect of PICP on tumor cell proliferation within the 48
days of the experiments.
PICP treatment had an early and continuing effect in pro-
moting vessels formation and development. By hematox-
ylin-eosin staining, in all the PICP-treated tumors more
vessels were detected since 14 days, and by 21 days the
PICP-treated tumors had larger vessels than contro-lateral
control tumors, these differences persisting up to 48 days
(Fig. 2). The vessels detected in PICP-treated tumors since
14 days were pervious and there was an outstanding dif-
ference from control tumors in the presence of red cells in
these vessels (identified also by tricromic Masson's stain,
not shown).
Mitotic and apoptotic indexes and tumor weight Figure 1
Mitotic and apoptotic indexes and tumor weight. A) 
Mitosis. B) Apoptosis. Slides were prepared from criopre-
served tumors. Respectively, were analyzed slides from 
tumors for each condition derived from 3 mice at 7 days, 8 
mice at 14 days, 6 mice at 21 days and 9 mice at 28 days. 
Slides were stained with Giemsa and with Hoechst stain. The 
results were similar for either stain and here are presented 
the data from Giemsa stained slides. For each slide at least 
1000 cells were screened in randomly chosen fields, for a 
total of cells varying from 3000 to 9000 per point in each 
condition. Bars indicate S.D. C) Weight in mg of dissected 
tumors. 3 tumors for each condition were analyzed at 7, 24, 
31, 38 and 48 days, and from 6 to 9 tumors for all other time 
points in each condition. Bars indicate S.D and the asterisks 
show the significance by one-way ANOVA. White columns 
are PBS-mock treatment controls and black columns are 
PICP-treated tumors.BMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
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Endothelial cells in the vessels were stained with an anti-
body to CD31 in slices from frozen tumors, or with an
antibody to CD34 in paraffin embedded tumors. These
antibodies detected endothelial cells at earlier times and
with higher frequency in the PICP-treated tumors (Fig. 3,
left panel) and confirmed the persistence in time of a
more developed vascularization in PICP treated tumors
(Fig. 3, left and right panels). Given the ramification and
thus, presumably, the tridimensional extension of the ves-
sels found in PICP-treated tumors we decided not to
present the data as vessel count/per area, which would not
add substantial information on and might mis-represent
their numbers and we show only the evidence obtained by
the histology and by immunodetection studies. The effect
of PICP in promoting rapid vessels formation and organ-
ization might be resultant from its chemoattractant effect
on endothelial cells, shown in vitro studies [37].
By In Situ Hybridization we analyzed the tumors for the
expression of 3 genes whose co-expression is considered a
metastatic signature in breast carcinomas, MMP-9, VEGF-
A and CXCR4 (Figures 4 to 6, top two rows). During the
development of the tumors the level of mRNA of each
gene changed with a slightly different temporal pattern.
For MMP-9 (Fig. 4) the highest mRNA expression was
found in PICP-treated tumors at 24 and 31 days, declining
thereafter (Fig. 4 top row). This corresponded to a steady
increase in number of cells positive for the protein by
immunostain up 48 days of growth (Fig. 4, third row) in
PICP-treated tumors. The control tumors showed lesser
expression of MMP-9 mRNA at all times, localized to indi-
vidual cells (Fig. 4 second row). Single cells or, only at
time 48 days, small clusters of cells were positive for the
protein, detected by immunostain (Fig. 4 bottom row).
For VEGF-A (Fig. 5), PICP-treated tumors showed higher
expression of mRNA than control tumors at all times of
Morphology of subcutaneous tumors in xenografts of MDA  MB231 in presence or absence of PICP Figure 2
Morphology of subcutaneous tumors in xenografts of 
MDA MB231 in presence or absence of PICP. Histol-
ogy of subcutaneous tumors generated by MDA MB231 and 
injected weekly with either vehicle or with PICP. Slices of cri-
opreserved tumors collected after 14, 21 days and of paraffin 
embedded tumors at 48 days were stained with hematoxylin 
and eosin. Micrographs from individual tumors shown here 
are representative of the findings in 3 to 8 tumors for each 
time point. Note the presence of large vessels containing 
blood cells in the PICP-treated tumors, not observed in the 
control tumors, at 21 days and the diffuse presence of vessels 
at 48 days in C3 treated tumors. Enlargement is: first row 
50×, second and third row 100×.
Vessel formation in subcutaneous tumors in xenografts of  MDA MB231 in presence or absence of PICP Figure 3
Vessel formation in subcutaneous tumors in 
xenografts of MDA MB231 in presence or absence of 
PICP. Immunohistochemistry and immunofluorescence 
identify CD31- and CD34-expressing endothelial cells. Exem-
plary micrographs of tumors are shown out of 3 to 9 tumors 
examined for each time point. Left: Sections from criopre-
served tumors dissected after 14, 21 and 28 days are proc-
essed for immunohistochemistry with CD31 antibody, 
followed by a secondary antibody conjugated either with 
TRITC (A, B and G, H) or biotin (C-F). Bar is 50 μm for A-D 
and G-H, and 25 μm for E-F. Sections from paraffin embed-
ded tumors dissected after 24 and 38 days are decorated 
with antibody to CD34 and revealed by Immunoperoxi-
dase.100× Bar is 50 μm.BMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
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explant (Fig. 5, top 2 rows). In both PICP-treated and con-
trol tumors, the highest level of expression of mRNA was
at 48 days and the expression was detected in the majority
of the tumor cells in PICP-treated tumors. By immunos-
tain of the protein (Fig. 5, bottom two rows), VEGF-A
expression was more diffuse in PICP-treated tumors,
while in control tumors the positive cells grouped in clus-
ters.
For CXCR4 (Fig. 6) the level of mRNA expression at all
times was much higher in the PICP-treated tumors than in
contro-lateral tumors (Fig. 6, two top rows). In these first,
high expression was confined to large clusters of cells at 24
and 31 days and virtually all the cells expressed CXCR4
mRNA by 48 days. The expression of the protein followed
in amounts that of the mRNA, with compartments more
intensely stained than others up to 38 days, and virtually
all the cells positive for CXCR4 in PICP-treated tumors
explanted after 48 days (Fig. 6, third row). Less cells and
less intensely stained were seen in the corresponding con-
trol tumors (Fig. 6, bottom row).
The treatment with PICP thus caused precocious expres-
sion of the above mentioned genes, and supported their
increased expression during tumor progression. These
data show the induction of a metastatic-prone phenotype
by the tumor cells in the presence of PICP. We suggest that
this occurs by an epigenetic event, since, by cell growth
and death measures and considering the overall tumor
growth, there is no significant difference between treated
and untreated tumors that could accommodate selective
advantage for clones of cells that in presence of PICP
would overgrow the other cells, unless these are already at
MMP-9 expression in PICP-treated and untreated contro-lat- eral tumors Figure 4
MMP-9 expression in PICP-treated and untreated 
contro-lateral tumors. Micrographs are representative of 
the results obtained from the analysis of at least two series of 
contro-lateral tumors treated or untreated with PICP. On 
the top is indicated the day after implant when the tumors 
were explanted. The two topmost rows are analysis by ISH 
and the two lower rows are analysis by immunoperoxidase 
for MMP-9. Bar is 25 μm.
VEGF-A expression in PICP-treated and untreated contro- lateral tumors Figure 5
VEGF-A expression in PICP-treated and untreated 
contro-lateral tumors. Micrographs are representative of 
the results obtained from the analysis of at least two series of 
contro-lateral tumors treated or untreated with PICP. On 
the top is indicated the day after implant when the tumors 
were explanted. The two topmost rows are analysis by ISH 
and the two lower rows are analysis by immunoperoxidase 
for VEGF-A. Bar is 25 μm.BMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
Page 7 of 10
(page number not for citation purposes)
time of implant a majority of the population. In addition,
in vitro studies in the MDA MB231 cells used for these
implants have shown that the induction of VEGF-A and
CXCR4, involving the majority of cells, occur in a timely
sequence upon treatment with PICP in a time lapse equiv-
alent to less that 2 population doublings [36].
It is likely that, once the high concentrations of PICP in
the implant chemoattracts endothelial cells, the enhanced
expression induced by PICP of the 3 gene products
described above will determine also the creation of a
microenvironment that favors endothelial cells growth
and organization in vessels [35-37]. In particular, VEGF-A
acts as survival factor for endothelial cells, and its up-
modulation by PICP in the tumor can determine para-
crine stimulation of endothelial cells. We have previously
demonstrated that Nrp-1 induces high levels of VEGF-A
expression via p38/PKC mediated pathways, and that up-
regulation of CXCR4 could result from the activation of
an autocrine loop of VEGF/CXCR4 [36]. In vivo, this
could make the tumor cells able to activate the paracrine/
autocrine loop CXCR4/CXCL-12/VEGF, when CXCL-12 is
expressed in the breast stroma.
We tested the tumors for CXCL-12 expression by immu-
nohistochemistry. In both untreated and PICP-treated
tumors CXCL-12 was not detectable up to 38 days, and it
was detected in the stromal compartment of both kind of
tumors only at day 48, with a slight higher intensity and
CXCR4 expression in PICP-treated and untreated contro- lateral tumors Figure 6
CXCR4 expression in PICP-treated and untreated 
contro-lateral tumors. Micrographs are representative of 
the results obtained from the analysis of at least two series of 
contro-lateral tumors treated or untreated with PICP. On 
the top is indicated the day after implant when the tumors 
were explanted. The two topmost rows are analysis by ISH 
and the two lower rows are analysis by immunoperoxidase 
for CXCR4. Bar is 25 μm.
CXCL-12, RECK and TIMP-2 expression in PICP-treated and  untreated contro-lateral tumors Figure 7
CXCL-12, RECK and TIMP-2 expression in PICP-
treated and untreated contro-lateral tumors. Micro-
graphs are representative of the results obtained from the 
analysis by immunoperoxidase of at least two series of con-
tro-lateral tumors treated or untreated with PICP. On the 
right side is indicated the day after implant when the tumors 
were explanted. A) with antibody to CXCL-12, B) with anti-
body for RECK; C) with antibody for TIMP-2. Bar is 25 μm.BMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
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diffusion in PICP-treated tumors (Fig. 7A). This suggests
that the induction of specific genes and the formation of
vessels in PICP-treated tumors is a CXCR4/CXCL-12-inde-
pendent event, that occurs early during tumor develop-
ment, and possibly preceding the effects on tumor growth
and vascularization reported to occur at later times in an
in vivo model of co-implant of CAF and tumor cells [14],
or reported by implanting an highly metastatic cell line in
experiments with timings of explants similar to ours [38].
We have also tested the tumors for other gene products
that are known to affect the proteolysis of ECM, which is
associated to angiogenesis and metastaticity. We show
that the expression of RECK is up modulated in control
tumors from 24 to 48 days and much less so in PICP-
treated tumors (Fig. 7B). The inhibition of RECK up-regu-
lation mediated by PICP is coherent with the higher level
observed for MMP-9, which is directly negatively regu-
lated by RECK. Low expression of RECK is associated to
the acquisition of pro-metastatic capability in various
tumors [29,30].
The expression of TIMP-2 decreases in time in control
tumors, while it increases in PICP-treated tumors (Fig.
7C). Not withstanding the inhibitory role of TIMP-2 on
MMPs activity and its MMP-independent inhibitory role
in angiogenesis, TIMP-2 is first of all required in stechio-
metric amounts for MMP-2 activation by MT1-MMP [31].
We have shown MMPs to be induced in vitro by PICP
treatment of MDA MB231 cells [36]. TIMP-2 was also
shown to have alternative membrane receptors to MT1-
MMP, which determine inhibition of endothelial cell pro-
liferation and induce the expression of RECK [41]. How-
ever, the fact that we detected a lesser expression of RECK
in PICP-treated than in control tumors, suggests that the
up-regulation of TIMP-2 observed in the former tumors
does not increase RECK expression in our model. It has
already been suggested that the prevalent function of
TIMP-2, among its multiple potential roles, is dependent
from the specific biological context [42] and this concept
has accommodated the discrepant data on the modula-
tion of TIMP-2 in different kind of tumors. Given that
PICP induces higher level of expression also of MT1-MMP
in these xenograft tumors (our unpublished data), we sug-
gest that the increase in TIMP-2 production could be
titrated to the membrane in activation complexes with
MMPs.
Conclusion
PICP induces rapidly a metastasis-prone phenotype in the
cells of ectopic tumors developed by skin engrafted MDA
MB231 cells, not accompanied by effects on their growth.
The pro-metastatic changes include increase in the level of
expression of MMP-9, VEGF-A, CXCR 4 and decrease in
expression of RECK. The joint modulation of the levels of
expression of these genes in tumors has a prognostic value
for their metastacity. PICP also induces early and sus-
tained development of vessels in the treated tumors. Pro-
angiogenic factors are increased in the PICP treated tumor
context, where endothelial cells are recruited by chemoat-
traction from PICP. We envisage that here they find a
microenvironment prone for vessel formation and
growth.
In PICP-treated tumors the concurrent low expression of
RECK and high expression of MMP-9, and the induction
in tumor cells expression of MT1-MMP and MMP-2 will
push up the balance of proteolysis compared to control.
In this context the increase in expression of TIMP-2 might
also favor proteolysis. This would support tumor and
endothelial cells mobility.
All the changes described occur before detection of CXCL-
12 in the tumor stroma. The organization of stromal sects
in these implants is a relatively late event, occurring after
31 days. Only when these stromal sects are detected,
immunoreactivity for CXCL-12 is associated to the stro-
mal cells and this is not greatly different in control or PICP
treated tumor, leading us to suggest that all the effects of
PICP we have detected are independent from CXCR4/
CXCL-12 signaling.
Overall, the changes induced by PICP in tumors are con-
sistent with the sequential induction of gene expression
reported in vitro. They describe its role as a tumor pro-
moter acting early during tumor development and affect-
ing multiple events involved in the phenotypic transition
of tumor cells to pro-metastatic cells, as well as favoring
the endothelial cells colonization of the implant and the
formation of vessels within the tumors. The concomitant
occurrence of these changes could facilitate the diffusion
of primary tumors, a fact we did not yet investigate.
The pleiotropic effect of PICP on tumor phenotype and its
chemoattraction of endothelial cells offer the possibility
to investigate means to target the early epigenetic switch it
induces in primary tumors, a strategy that might prove
more efficient in the containment of tumors, that target-
ing a single up regulated metastatic gene.
In addition, the response to PICP of MDA MB321 cells
might offer a rationale for their preferential homing and
the better development of breast cancer metastasis in a
PICP-rich environment like bone. It can be hypothesized
that PICP could chemoattract the tumor cells preferen-
tially to the bone environment and that it could support
their osteolytic activity in this location. These aspects
require further investigation.BMC Cancer 2009, 9:59 http://www.biomedcentral.com/1471-2407/9/59
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